At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 552 enrolled
Drug / intervention
Brimonidine Topical Gel, 0.33 percent (Perrigo) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea
In Brief
A Phase 3 clinical trial evaluating Brimonidine Topical Gel, 0.33 percent (Perrigo), Brimonidine Topical Gel, 0.33 percent (Reference), and 1 other intervention for Rosacea. Completed, enrolled 552 participants.
Detailed Summary
To compare safety and efficacy of Perrigo's rosacea drug product compared to an FDA approved rosacea drug product in the treatment of facial erythema of rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedMar 2015
Primary CompletionDec 2015
TodayJul 2026
First PostedMar 11, 2015
Enrollment StartMar 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.3 years ago
Interventions
Brimonidine Topical Gel, 0.33 percent (Perrigo)drug
Brimonidine Topical Gel, 0.33 percent (Reference)drug
Placebo geldrug